RecruitingNCT05883072
Exploring the Effectiveness of AI Generative Models for Diabetic Patients
Sponsor
Pakistan Council of Scientific and Industrial Research
Enrollment
300 participants
Start Date
Jan 5, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
We plan to explore the usability of Generative AI-Chatbot for Diabetic Patient
Eligibility
Min Age: 18 YearsMax Age: 100 Years
Inclusion Criteria3
- Present physically in Pakistan
- Adults (18 years or older)
- Diabetic Patient
Exclusion Criteria3
- Adults unable to consent
- Individuals who are not yet adults (infants, children, teenagers)
- Prisoners
Interventions
BEHAVIORALExploring AI-Chatbot
All participants will be provided access to AI-Chatbot and will be asked to enquire their daily life problems related to diabetes. They will also be asked to review the replies of the Chatbot after their interaction.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05883072
Related Trials
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT070644731153 locations
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
NCT06112418115 locations
Project Dulce for Arab Americans With Type 2 Diabetes
NCT055805362 locations
Diabetes and Heart Disease Risk in Blacks
NCT000018531 location
Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes
NCT067623141 location